Later on, Kim et al. found that 2-DG, as a PD-L1 deglycosylation agent, synergizes with the epidermal growth factor receptor (EGFR) inhibitor, gefitinib, in syngeneic breast cancer models [13]. This evidence concerns the gene EGFR and breast cancer.